Preventive Osteopathic Treatment of Plagiocephaly (TOPP PLAGIO)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03780920|
Recruitment Status : Recruiting
First Posted : December 19, 2018
Last Update Posted : July 24, 2019
Positional cranial deformities (PCD), plagiocephaly and brachycephaly are a common reason for pediatric consultation, which has increased significantly since the recommendation to lay babies on their backs to prevent unexpected infant death (ILD). CPD is a source of concern for parents about their impact on psychomotor development and the aesthetic risk of deformity. The High Authority for Health (HAS) will soon put in place recommendations with a fact sheet for health professionals and the public. The aim of this research is to study whether early treatment of rotation disorders and hypertonia in newborns by manual osteopathic techniques would prevent the occurrence of positional deformities of the skull.
The main objective is to evaluate the effectiveness of an early osteopathic treatment on the rate of CPP (plagiocephalic and postural brachycephalia) at 4 months in newborns at risk.
the secondary objective is: to evaluate the effectiveness of an early osteopathic treatment on the quality of life of the child at 4 months.
Methodology: Controlled, randomized monocentric two-arm parallel study between (1) osteopathic follow-up and (2) osteopathy-free follow-up. The inclusion period will be 18 months and the follow-up period is 4 months.
Procedure: The two groups will be evaluated at 3 days and 4 months. The experimental group will benefit from an osteopathic treatment of 3 days of life to 4 months with a frequency of 3 to 4 sessions. Both groups will benefit from sleeping, carrying, positioning and stimulation advice.
The perspectives are:
- the decrease in the prevalence of CPP after early osteopathic treatment.
- Defining a decision algorithm for early osteopathic treatment.
- Subject to recommendations on the indication of early osteopathic treatment in neonates at risk.
|Condition or disease||Intervention/treatment||Phase|
|Positilonal Deformation of the Skull Head Turn Preference Axial Hypertony||Procedure: manual therapy/osteopathy||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||180 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Investigator, Outcomes Assessor)|
|Official Title:||Interest of an Early Osteopathic Treatment in Infants in the Prevention of Cranial Deformations : Positional Plagiocephaly and Brachycephaly.|
|Actual Study Start Date :||February 14, 2019|
|Estimated Primary Completion Date :||August 2020|
|Estimated Study Completion Date :||November 2021|
|Active Comparator: Osteopathic treatment||
Procedure: manual therapy/osteopathy
In this group, children will benefit from early osteopathic treatment over a period ranging from the third day to 4 months. The number of sessions will not be fixed, on average, 3 sessions will be carried out during this period at the University Hospital of Montpellier.
The duration of the session will be between 20 minutes to 30 or even 40 minutes
|No Intervention: Control group|
- Positionnal skull deformation : plagiocephaly and brachycephaly [ Time Frame: four month ]cranial vault asymetry index and cranial index measured with caliper between the age of 3 to 10 days and at 4 months measured blind of the randomization arm
- Questionnaire QUALIN [ Time Frame: fourth month ]the"questionnaire QUALIN" is a quality of life assessment questinniare for infant under 3 months of age, valided in Europe(French, Spanish, English and Italian)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03780920
|Contact: Guillaume CAPTIER, Prfirstname.lastname@example.org|
|Contact: Claire CHAUVETON||0467330924|
|CHU Arnaud de Villeneuve||Recruiting|
|Montpellier, Hérault, France, 34000|
|Contact: Guillaume CAPTIER, PU-PH 0467338761 email@example.com|
|Principal Investigator:||Guillaume CAPTIER, Pr||University Hospital, Montpellier|